Document Detail


High density lipoprotein cholesterol and statin trials.
MedLine Citation:
PMID:  18781948     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Epidemiological studies show that high density lipoprotein cholesterol (HDL-C) levels are inversely related to the risk of vascular events. Statins are the most widely prescribed drugs for the treatment of dyslipidaemias and their use for the prevention of vascular events is evidence based. Statins raise HDL-C but this effect seems to vary considerably between studies. We searched the literature to assess the relationship between statin-induced increases in HDL-C levels and surrogate and/or clinical endpoints. Based on the existing evidence, it is difficult to determine how much reduction, if any, in vascular risk is attributable to a statin-induced increment in HDL-C levels. Whether a statin that beyond its LDL-C lowering effect also raises HDL-C has additional benefits in the prevention of vascular events remains to be established.
Authors:
Anna Kakafika; Vasilios G Athyros; Konstantinos Tziomalos; Asterios Karagiannis; Dimitri P Mikhailidis
Related Documents :
2196808 - Some aspects of the relationship between oral contraceptives, lipid abnormalities, and ...
23073568 - Prognostic indicators for long-term disability in multiple sclerosis patients.
24599098 - Educational inequalities in obesity among mexican women: time-trends from 1988 to 2012.
11006058 - Population frequency distributions of hdl, hdl(2), and hdl(3) cholesterol and apolipopr...
22283838 - A risk score for early cytomegalovirus reactivation after allogeneic stem cell transpla...
7755918 - Sexual behaviour and risk of exposure to hiv among 18-25-year-olds in scotland: assessi...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Current medicinal chemistry     Volume:  15     ISSN:  0929-8673     ISO Abbreviation:  Curr. Med. Chem.     Publication Date:  2008  
Date Detail:
Created Date:  2008-09-10     Completed Date:  2008-10-16     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9440157     Medline TA:  Curr Med Chem     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  2265-70     Citation Subset:  IM    
Affiliation:
Second Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippokration Hospital, Thessaloniki, Greece.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Cardiovascular Diseases / drug therapy,  metabolism,  therapy
Cholesterol, HDL / chemistry,  metabolism*
Drug Combinations
Drug Therapy, Combination
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology*,  therapeutic use*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Cholesterol, HDL; 0/Drug Combinations; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Expression and function of cytochrome p450-dependent enzymes in human skin cells.
Next Document:  Nuclear receptors as potential molecular targets in cholesterol accumulation conditions: insights fr...